-
Mashup Score: 0Pleuropulmonary Blastoma DICER1 Syndrome Study - 1 year(s) ago
Pleuropulmonary blastoma (PPB) is a rare tumor of the lung that affects young children. The PPB DICER1 Syndrome Study an observational clinical research study is enrolling children with PPB and their families.
Source: ppb.cancer.govCategories: Genetics, Latest HeadlinesTweet
-
Mashup Score: 8Quitting Smoking and Other Tobacco Public Health Resources - 1 year(s) ago
Get free resources and materials to help you quit smoking, prevent youth use, and learn more about the effects of tobacco use.
Categories: General Medicine News, Latest HeadlinesTweet-
Remember every puff of a cigarette causes damage to your lungs. Find tips here to help you to quit smoking and give your lungs a chance to heal: https://t.co/L5o7JM1NBy via @FDATobacco #LCAM #LungCancerAwarenessMonth https://t.co/3h7pP5NItX
-
-
Mashup Score: 4Predicting Risks and Benefits for Lung Cancer Screening | NIH Intramural Research Program - 1 year(s) ago
IRP Researchers Refine Tools to Maximize the Benefit from Life-Saving TestsWednesday, November 16, 2022 Data analysis by a pair of IRP researchers has pointed to better ways to figure out which people would receive the most benefit from lung cancer screenings using computed tomography (CT) scanners like this one.Eleven years ago, IRP senior investigator Hormuzd Katki, Ph.D., had a bit of an…
Source: irp.nih.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Predicting Risks and Benefits for #LungCancer Screening - a new blog post about NCI researchers working to maximize the benefit of life-saving tests. https://t.co/z2jnPYSS3I @nciepitraining #LCSM #LCAM https://t.co/LHTb5htKNT
-
-
Mashup Score: 1Lung - ViewRay - 1 year(s) ago
MRIdian SMART for Lung Cancer For Patients Safely treat high-risk lung tumors, delivering ablative doses with less toxicity With more than 2 million cases diagnosed yearly, lung cancer is the most common type of cancer.1 And, with more than 1.7 million lung-cancer related deaths annually, also the deadliest.1 The high rate of mortality is attributed to two … Lung Read More »
Source: ViewRayCategories: Hem/Oncs, Latest HeadlinesTweet-
I'm increasingly getting asked by patients what MR-guided SBRT can do for their lung cancer. Fortunately, @viewray has a new video that can help. #lcam #lcsm #radonc https://t.co/Li498SeORG https://t.co/vf5n72rHXw
-
-
Mashup Score: 0VA Researchers Find High Risk Of Lung Cancer In Older Smokers Previously Considered Low Risk | VA Washington DC health care | Veterans Affairs - 1 year(s) ago
Washington DC VA Medical Center Physician Researchers have found that current and former older smokers, who were previously not recommended for annual lung-cancer screening, may have a high risk of lung cancer.
Source: Veterans AffairsCategories: Hem/Oncs, Latest HeadlinesTweet-
"older, current, or former smokers, who are not recommended for annual lung cancer screening, are 1000% more likely to develop lung cancer". #lcam #lcsm https://t.co/b093KiKG3l https://t.co/yCqGygrDns
-
-
Mashup Score: 1
Fred Hutchinson Cancer Center lung cancer scientists open a human trial after preclinical work shows that making small cell lung cancer more visible to immune cells can make the tumors more responsive to immunotherapy.
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A new #clinicaltrial for patients with small cell #lungcancer, #SCLC, is enrolling participants after a team of researchers in the lab of @DMacPhersonLab showed an experimental drug could make #immunotherapy more effective against the deadly disease. https://t.co/umAn55YznK #LCAM
-
-
Mashup Score: 0Longer Intervals Between Lung Cancer Screens Could Reduce False-Positives for Low-Risk Patients - 1 year(s) ago
Personalized intervals for lung cancer screening—based on individual factors and recent screen results—could help improve efficiency and reduce harms such as false-positives in lower-risk patients, study finds.
Source: National Cancer InstituteCategories: Genetics, Latest HeadlinesTweet-
#NCI_Biostatistics investigators developed a personalized approach to choose how long to wait between #LungCancer screenings, which could help reduce false positives and improve efficiency @JNCI_Now https://t.co/yUnfcwogRw #LCAM
-
-
Mashup Score: 6Real-world studies indicate NSAIDs improve lung cancer survival | Frederick National Laboratory - 1 year(s) ago
Common drugs for controlling pain and inflammation – such as aspirin and ibuprofen – improved overall lung cancer survival by a statistically significant margin in a long-term study of patient medical records. This finding called for more definitive randomized clinical trials.
Source: Frederick National LaboratoryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A study of patient medical records has found a link between common drugs for controlling pain and inflammation – such as aspirin and ibuprofen – and survival in lung cancer. This finding called for more definitive randomized clinical trials. https://t.co/QlxBdID0IO #LCAM 🫁 https://t.co/bvx11qwWRk
-
-
Mashup Score: 1Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis - 1 year(s) ago
First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced NSCLC. We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival.
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Pooled analysis of 1L nivolumab + ipilimumab in NSCLC @Annals_Oncology. Included data from 1332 pts enrolled in CheckMate 227, 817, 568, 012 and showed RR 36%, mDOR 23.7m, mPFS 5.4m, mOS 18.6m, 3y OS rate 35%. #LCSM #LCAM https://t.co/ZS6io5HJXX
-
-
Mashup Score: 0
Fred Hutchinson Cancer Center lung cancer scientists open a human trial after preclinical work shows that making small cell lung cancer more visible to immune cells can make the tumors more responsive to immunotherapy.
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A new #clinicaltrial for patients with small cell #lungcancer, #SCLC, is enrolling participants after a team of researchers in the lab of @DMacPhersonLab showed an experimental drug could make #immunotherapy more effective against the deadly disease. https://t.co/umAn55Z7di #LCAM
-
.@theNCI clinical study of pleuropulmonary blastoma is enrolling patients and families. Learn more: https://t.co/MG8Ks8vWq7 #LCAM #NCI_ClinicalGenetics https://t.co/astnXJaNLm